Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? by Foppa, Murilo et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Cardiovascular Ultrasound
Open Access Review
Echocardiography-based left ventricular mass estimation. How 
should we define hypertrophy?
Murilo Foppa*, Bruce B Duncan and Luis EP Rohde
Address: Graduate Studies Program in Cardiology. School of Medicine. Federal University of Rio Grande do Sul. Porto Alegre – RS. Brazil
Email: Murilo Foppa* - mfoppa@cpovo.net; Bruce B Duncan - bbduncan@orion.ufrgs.br; Luis EP Rohde - lerohde@terra.com.br
* Corresponding author    
cardiovascular diseaseechocardiographyepidemiologygeometric patternshypertrophyleft ventricularmalerisk factorsultrasonography
Abstract
Left ventricular hypertrophy is an important risk factor in cardiovascular disease and
echocardiography has been widely used for diagnosis. Although an adequate methodologic
standardization exists currently, differences in measurement and interpreting data is present in
most of the older clinical studies. Variability in border limits criteria, left ventricular mass formulas,
body size indexing and other adjustments affects the comparability among these studies and may
influence both the clinical and epidemiologic use of echocardiography in the investigation of the left
ventricular structure. We are going to review the most common measures that have been
employed in left ventricular hypertrophy evaluation in the light of some recent population based
echocardiographic studies, intending to show that echocardiography will remain a relatively
inexpensive and accurate tool diagnostic tool.
Introduction
The diagnosis of left ventricular hypertrophy (LVH) has
been incorporated in the clinical practice as an important
marker of cardiovascular disease. Its prevalence depends
on classification criteria and specific population charac-
teristics, ranging from 3% in normotensive community-
based samples [1] to about three-quarters of hypertensive
patients [2]. Irrespective of other risk factors, those in the
upper distribution of left ventricular mass have their risk
at least duplicated for future cardiovascular morbidity and
mortality, as summarized in one metanalysis [3].
Echocardiography has been clinically employed for more
than 30 years, becoming one of the most important non-
invasive imaging methods in the evaluation of cardiac
morphology and dynamics. However, the apparent sim-
plicity in LVH evaluation by echocardiography conceals
several intrinsic and usually unrecognized critical steps
that may limit its clinical validity.
This manuscript introduces the basic principles of left ven-
tricular mass (LV mass) estimation by echocardiography,
focusing on the potential limitations and discrepancies of
such measurement, in order to provide the appropriate
background for understanding the rather complex issue of
defining the cut-off values for LVH diagnosis in popula-
tions. Although advances in echocardiographic tech-
niques has minimized the impact of many of the
methodological details discussed here, an understanding
of these topics is important, since most of the clinical and
epidemiologic studies currently published are based on
the echocardiographic criteria here described. We also
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intend to give a critical evaluation of the diagnostic per-
formance and clinical validation of this imaging method.
Left Ventricular Measurement
Left ventricular mass is generally calculated as the differ-
ence between the epicardium delimited volume and the
left ventricular chamber volume multiplied by an estimate
of myocardial density. Following this principle, several
methodologies have been used to calculate left ventricular
mass and to define hypertrophy with its own flaws and
strengths on each step (Table 1), resulting in a wide range
of values. Probably, the most significant echocardio-
graphic limitation is related to inadequate quality imag-
ing. Population-based studies are not able to obtain
complete imaging in almost a quarter of screened patients
[4,5]. mainly due to inappropriate acoustic windows.
Imaging – Mode and Acquisition
Both M-mode and two-dimensional imaging can be
employed to calculate left ventricular mass. M-mode
imaging allows better endocardial border definition as it
has greater resolution due to higher frame-rate, as long as
adequate ultrasound beam positioning is ensured and
ventricle shape approaches normality. Two-dimensional
imaging, on the other hand, depicts the "real" ventricular
shape and identifies regional motion abnormalities.
However, the quality of two-dimensional imaging may be
limited due to both lower lateral resolution and frame-
rate. Additionally this option is more time consuming,
limiting its use in epidemiological studies. Two-dimen-
sional images are usually acquired both in paraesternal
and apical views, depending on the geometrical formulas
that are used.
Technological advances have joined both methods and
partially minimized their limitations There are standard-
ized and validated recommendations for the clinical use
of two-dimensional determination of LV mass [6], How-
ever, two-dimensionally oriented M-mode, obtaining
images perpendicularly from the longitudinal axis slightly
above the papillary muscle level is widely employed in
clinical practice and is accepted as an adequate alternative
in epidemiological studies. Digital imaging has also made
it possible to reconstruct diverse M-mode planes from
two-dimensional images (so called anatomical M-mode),
allowing better positioning, although the final image res-
olution is that of two-dimensional images. Although
accurate [7], LV mass estimation using anatomical M-
mode has not been adequately validated in clinical stud-
ies. Two-dimensional mode has also improved due to
refined imaging processing technology, particularly sec-
ond harmonic imaging. Also, built-in software for auto-
matic border detection has been developed allowing
calculation of real-time volumes. Although most of these
newer technologies are widely available in commercially
available ultrasound equipment, their potential for pro-
viding additional accuracy in the evaluation of LVH
remains poorly characterized.
A relevant degree of variability in LV mass determination
could be attributed to online measurement inaccuracies
due to lower imaging resolution of older equipment,
which could reach 10% of parietal thickness. Nowadays,
variability due to on-line or off-line analysis of digitalized
images calculations is of considerably smaller magnitude
[8].
We will focus our discussion on M-mode estimation of LV
mass, since most epidemiological reports use this imaging
modality. Preference for M-mode is based on its technical
feasibility and availability at the time when most studies
were performed. However, despite adequate correlation
with two-dimensional measurements [9], M-mode has
been suggested to averagely underestimate LV mass in
about 20 g [10]. Theoretically, two-dimensional imaging
would be more adequate in samples of patients with
cardiovascular disease, where LV shape assumptions play
a critical role in LV mass estimation.
Estimating Left Ventricular Volume
Determination of left ventricular volumes is accom-
plished using formulas that fit ventricular shape to pri-
mary geometric figures. Ellipse, cylinder, cone, and
truncated polyhedrons have been employed and vali-
dated in normally shaped ventricles, although most stud-
ies have limited sample sizes [11]. Some geometrical
assumptions are best fit using two-dimensional images
while others can be performed assuming geometric forms
from M-mode imaging.
If a two-dimensional approach is used, both area-length
and truncated-ellipsoid models are feasible and reasona-
bly accurate, with validated formulas [6]. Among other
formulas for volume calculation, the modified Simpson's
Table 1: Critical Steps in Determining and Interpreting Left 
Ventricular Hypertrophy using Echocardiography
1. Imaging – Mode and Acquisition
2. Estimating Left Ventricular Volume
3. Defining Border Limits – Conventions of Layer Measurements
4. Calculating Mass – LV Mass Formulas
5. Indexing for Body Size
6. Determining Cut-off Points
a. Using a reference sample (normality/statistical criteria)
b. Using prognostic data (driven by clinical endpoint)
7. Evaluation of Left Ventricular Structure
8. Role of Additional Factors in LVM Determination
9. Clinical Correlates Associated with LVHCardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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Discs Rule, which is greatly facilitated nowadays by built-
in software, offers flexibility that allows accurate estima-
tion of left ventricular volumes even in greatly distorted
ventricles. Even though volumes determined by Simp-
son's Rule are frequently used for ventricular function
determination, they are not routinely used to calculate LV
mass, probably due to limitations resulting from poor epi-
cardial delimitation in some patients. Other geometrical
models have been proposed in the past [12,13], with var-
iable use in clinical practice.
The method of cubed formulas, which incorporate only
one dimension of the left ventricular cavity and assume an
ellipsoid geometry, is the most widely used to calculate
left ventricular volumes and mass in noninvasive labora-
tories worldwide. The broad acceptance of M-mode
derived estimation relies on the fact that it was the first
method that was validated and also on its technical sim-
plicity. The one-dimensional approach, however, imposes
more strict geometrical assumptions and amplifies the
risk of inaccuracy, as measurement errors are cubed.
Defining Border Limits – Conventions of Layer 
Measurements
Ultrasound signals are reinforced where surfaces change
density, allowing definition of limits between surface lay-
ers. The inclusion or exclusion of these echoes from inter-
faces of the left ventricular cavity or myocardial wall can
cause significant discrepancies in the overall measure-
ments [14]. Initial M-mode standard recommended inclu-
sion of the edges as part of interventricular septum
thickness, but exclusion of the posterior wall epicardial
edge [15]. Investigators of the University of Pennsylvania
developed a criteria (The Penn Convention) in which all
edges are not included in parietal thickness measure-
ments, but are considered as part of the ventricle cavity
[16]. This approach underestimate LV mass when com-
pared to the M-mode convention, proposed by the Amer-
ican Society of Echocardiography (ASE). This latter
convention (ASE) is the most accepted border definition
criteria, becoming the standard recommendation for M-
mode estimations, and uses the leading edge of each layer
[17](Figure 1). Employing Penn and ASE convention with
the same volume formulas may originate LV mass discrep-
ancies in the range of 15% in men and 18% in women
[18]. Measurement convention must be acknowledged
and adequately corrected for in comparisons of clinical
studies of LVH.
In the past few years, spatial resolution of transthoracic
echocardiography has greatly enhanced, leading to major
improvements in image quality. Most of this progress can
be attributed to second harmonic imaging, that signifi-
cantly increases signal-to-noise ratio by receiving only
harmonic frequencies. Although this technology is now
widely available in most ultrasound equipment, its poten-
tial accuracy to evaluate LVH remains poorly character-
ized. A recent study suggests that LV mass estimations
using second harmonic imaging can cause as much as a
26% increment in mean LV mass index corrected for body
surface area, when compared to standard fundamental
imaging using similar formulas and conventions [19].
This is probably due to an increase in border refringency.
Calculating Mass (Left Ventricular Mass Formulas)
The most commonly used formulas to estimate LV mass
are all variations of the same mathematical principle,
based in the volume formulas stated above. Original cal-
culations from Troy and coworkers were the first to be rec-
ommended as standard to estimate LV mass from M-
mode measurements (Formula 1) [15].
Formula 1: LV mass(Troy) = 1.05 ([LVIDD + PWTD +
IVSTD]3- [LVIDD]3) g.
Where: LVIDD = Left Ventricular Internal Diameter in
Diastole
PWTD = Posterior Wall Thickness in Diastole
IVSTD = Interventricular Septum Thickness in Diastole
Subsequently, Devereux and colleagues suggested a
slightly modified regression equation, using the Penn
convention as the border definition criteria (Formula 2).
Their prediction equation in this pivotal study was
derived from necropsy findings of 34 patients [16].
Formula 2: LV mass(Penn) = 1.04 ([LVIDD + PWTD +
IVSTD]3- [LVIDD]3) -13,6 g.
As depicted above, each regression equation was derived
based on a specific border limits convention, an issue that
is source of great confusion when interpreting different
studies [20]. As expected, LV mass calculations derived
from both formulas are linearly correlated, but final crude
estimations may differ by more than 20%. Devereux and
colleagues proposed a new adjusted equation, validated
on necropsy findings of 52 individuals [21], using the ASE
convention and accounting for this discrepancy (Formula
3).
Formula3: LVmass(ASE): 0.8 (1.04 ([LVIDD + PWTD +
IVSTD]3- [LVIDD]3))+ 0,6 g.
Some critical aspects must be acknowledged regarding LV
mass formulas. First, all necropsy validation studies have
limited sample sizes and evaluate heterogeneous ventricu-
lar configurations. Second, these formulas may not per-
form adequately in distorted ventricles, where a two-Cardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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dimensional approach is preferred. Different formulas
may yield distinct cut point values, as demonstrated by
Levy and coworkers in the Framingham cohort [18].
Finally, other post-mortem study showed only moderate
correlation between echocardiographic and autopsy LV
mass estimations (correlation coefficients ranging from
0.58 to 0.67) [22].
Indexing for Body Size
Both body size and body habitus are clearly associated
with LV dimensions and mass. Diverse normalization and
indexes were created and tested to adjust for three differ-
ent sources of physiologic variation in LV mass: lean body
mass, obesity, and gender. However, the interdependence
of such associations should be carefully understood to
allow an adequate correction of LV mass without distort-
ing its association with cardiovascular disease.
Several indexes for body size correction have been pro-
posed, such as height, diverse allometric height adjust-
ments, weight, body surface area, body mass index, and
free-fat mass. The best way for normalization of LV mass
is still controversial and another source of confusion.
Different body-size adjustment criteria and their standard
cut points result in different prevalence of patients with
LVH [18]. Not surprisingly, those with higher LV mass are
more frequently classified as hypertrophic by different
classifications simultaneously [23].
The body surface area correction, using the Dubois for-
mula [24], reduces variability due to body size and gender
[25], but this index underestimates LV mass in the upper
range of the body surface area distribution [26]. A correc-
tion based on height alone would allow evaluation of the
separate role of obesity in LVH as proposed by Levy and
coworkers [18].
Adjustment of LV mass with body surface area would
imply that obese patients are expected to have higher LV
mass estimations per se. In this scenario, height-based
adjustments can more accurately estimate LV mass and
the resulting cardiovascular risk associated with LVH in
Comparison between M-mode border measurement conventions Figure 1
Comparison between M-mode border measurement conventions. The Standard convention measures from leading to trailing 
edge in the septum and from leading to leading edge of the posterior wall. Penn criteria excludes echoes from parietal walls 
while ASE criteria measure leading to leading edge. (LVDd: Left Ventricular Diameter in Diastole).Cardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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the obese. This turns to be particularly relevant in risk
stratification due to the frequent clustering of hyperten-
sion, obesity and LHV. Different allometric height-based
adjustments have been used. Height2.7, derived from
regression models in normal samples from De Simone
and coworkers [26], appears to offer the most accurate
estimation of LV hypertrophy and risk factors for patho-
logic changes in the heart structure, particularly in obese
subjects. Zoccali and colleagues found LVH indexed by
height2.7 to be a better predictor of cardiovascular events
than LVH indexed using body surface area in a group of
patients under dialysis [27]. Liao and colleagues [28]
studied 988 patients and identified progressive incre-
ments in death rates with both body surface area and with
height2.7 indexing criteria. Subjects simultaneously classi-
fied as LVH with body surface area and height2.7 criteria
had increased average LV mass and a 3-fold increase in
death rates, while those classified as LVH only when
indexed by height indexes had no increase in future cardi-
ovascular events. In summary, it appears prudent to favor
indexes that do not adjust for obesity, such as height, and
height2.7, particularly in studies in which the independent
impact of obesity is in question. Body surface area index-
ing permits adequate classification of most of patients in
clinical practice, incorporating in LVH determination
some of the risk associated with obesity.
Finally, men have increased LV mass and at least part of
this effect can be attributed to body size differences. Gen-
der differences in LV mass are first noticed around puberty
and can be minimized although not eliminated by ade-
quate indexing of body size [29]. Due to this difference in
LV mass, some criteria for body size adjustments use gen-
der-specific cut points for normality as will be seen below.
Determining Cut-off Points
The determination of cut points in biological variables to
define abnormality is frequently a source of controversy,
and can be driven by different strategies. The definition of
what constitutes an abnormal LV mass is no exception to
this rule.
Left Ventricular hypertrophy diagnosis defined by deviation from 
mean
LV mass as most biological variables are statistically dis-
tributed in normal or skewed curves. One can consider the
diagnosis of LV hypertrophy in those who are in the
extreme right tail of a "Gaussian" distribution, such as
beyond two standard deviations of a reference sample of
normal individuals. Identification of a "normal represent-
ative sample" is not trivial and most studies use relatively
small samples. In the late 80s, Levy and coworkers. [18]
published a landmark paper evaluating a subset of indi-
viduals without known cardiovascular risk factors in the
Framingham Cohort. These authors calculated LV mass
both with the ASE convention and Troy equation (For-
mula 1) and with the Penn Convention and Devereux
equation (Formula 2) to estimate LV mass, and proposed
normal limits for LV mass for men and women, based on
cut points at two standard deviations above the mean and
using several indexes for body size correction (Table 2).
These criteria are widely used in clinical practice and
research, despite limitations in representativeness, as they
may not perform well in non-white populations.
Left Ventricular hypertrophy defined by prediction of clinical disease
Increase in LV mass has been shown to be an independent
prognostic factor for intermediate endpoints [30] and
clinical outcomes such as major cardiovascular events and
mortality [31,32]., total mortality [27,28,33] and sudden
death [34]. However, the risk associated with increases in
several "physiological" variables is mostly linear over a
great range of variation. This behavior has already been
suggested for blood pressure [35] and cholesterol levels
[36], leading to aggressive management strategies ("the
lower the better"). In fact, Levy and colleagues demon-
strated a progressive increase in risk associated to LV mass,
even at levels not considered as "hypertrophic". Cardio-
vascular disease and death rates had a 1.5-fold increase for
Table 2: Left ventricular hypertrophy cut points (Healthy reference group from The Framingham cohort).
Men Women
Mean Mean + 2sd Mean Mean + 2sd
LVM(ASE) (g) 208 294 145 198
LVM(Penn) (g) 177 259 118 166
LVM/BSA(ASE) (g/m2) 109 150 89 120
LVM/BSA(Penn) (g/m2) 92 131 72 100
LVM/Ht(ASE) (g/m) 117 163 89 121
LVM/Ht(Penn) (g/m) 99 143 73 102
Adapted from[18].Cardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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each 50 g/m of LV mass indexed by height [31]. In a subset
of hypertensive patients [32], cardiovascular disease
increased monotonically with more than a 4-fold increase
in risk between the lowest and highest LV mass quintiles.
In this study, clinically relevant increment in risk was
identified in patients with LV mass below the limits usu-
ally employed for LVH definition.
These findings suggest that traditional cut-off limits may
ignore cardiovascular risk associated with increased LV
mass in the "normal" range based on statistical assump-
tions. De Simone and coworkers introduced the concept
of inappropriate LV mass increase [37] to use LVH within
the context of risk prediction employing multiple factors.
It is considered a clinical relevant LV mass increase values
above 128% of a predicted LV mass based on gender, esti-
mated stroke volume and height2.7 [38,39]
Moreover, LVH regression has been used in clinical trials
as a favorable prognostic marker. A metanalysis has
shown in hypertensive patients that the regression of LVH
predicts a reduction of more than 50% in cardiovascular
events[40]
Evaluation of Left Ventricular Structure
Alternative concepts to LVH in the determination of left
ventricular adaptive processes that take place in the over-
loaded ventricle assesses the fundamental components
used in LV mass estimations, namely wall thickness and
diastolic chamber dimension. The expected pathophysio-
logical response of each of these components is theoreti-
cally distinct, as pressure overload leads to increased wall
thickness and volume overload leads to chamber dilation.
These differences cannot be assessed solely by LV mass
calculations.
Relative Wall Thickness
Parietal thickness and its relation to LV chamber size have
been recognized as measures of hypertrophy for more
than 30 years [41]. Relative wall thickness (RWT) is meas-
ured in clinical studies both as: 2 * posterior wall thick-
ness divided by LV diastolic diameter or, septal wall
thickness + posterior wall thickness divided by LV diasto-
lic diameter. Even thought these measures have been used
interchangeably by some investigators, septal asymmetry
(IVSTD/PWTD > 1.3) was present in about 5% of Fram-
ingham subjects [42] and can lead to an underestimation
of relative thickness when only posterior wall thickness is
used. The reference cut point value for increased relative
wall thickness derived from upper limits of normal sam-
ples is usually 0.44 [43] or 0.45 [42], irrespective of which
formula is used. RWT provides information regarding LV
geometry independent of other calculations [44], preclud-
ing the requirement of most corrections. Nevertheless, sig-
nificant LVH can occur without major changes in RWT,
particularly when simultaneous pressure and volume
overload are present.
Geometric Patterns
Attempts have been made to evaluate separately adaptive
responses in parietal thickness increase and in dilation.
Initially, Savage and coworkers [42] stratified Framing-
ham patients with LVH in subgroups as: disproportionate
septal LVH; concentric LVH; eccentric-dilated LVH, and
eccentric non-dilated LVH. They identified in the 3 last
categories increasing levels of systolic blood pressure, uti-
lizing retrospective blood pressure data from 30-years of
the cohort follow-up, suggesting a progressive character of
adaptive mechanisms. A later approach defined 4 distinct
geometric patterns: normal geometry, concentric
remodeling, concentric hypertrophy and eccentric hyper-
trophy (Figure 2). Ganau and coworkers [43], using
echocardiographic hemodynamic estimates, reinforced
the impression that the geometric patterns parallels pro-
gressive hemodynamic changes. Hypertensive target
organ disease measured by fundoscopic alterations are
also more frequent in hypertrophic geometric patterns
[30].
Koren and coworkers [45] used cut points of 125 g/m2 for
LVH and 0.45 for RWT in a sample of hypertensive
patients and found a 10-year incidence of cardiovascular
events of 31% in those with concentric hypertrophy com-
pared to 11% in those with normal geometry. In 1995,
Geometric Patterns Figure 2
Geometric Patterns.Cardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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two cohorts studies were simultaneously published evalu-
ating geometric patterns impact in the incidence of cardi-
ovascular events. Verdecchia and colleagues [46] studying
694 patients with body surface area indexed LV mass
lower than 125 g/m2, without additional adjustment for
obesity and other metabolic risk factors, found a relative
risk of 2.6 in the 272 patients with concentric remodeling
compared to normal geometry patients. Krumholz and
coworkers [47], studied 3209 from The Framingham
study, indexed LVM by height using cut points of 143 g/m
in men and 102 g/m in women and adjusted the models
for obesity and other relevant covariates. Their analysis
showed a relative risk of 2.1 for all cause mortality with
concentric hypertrophy, but not additional risk in those
classified as concentric remodeling. Relative risk became
nonsignificant when a correction for LV mass was
included in the models. Verdecchia and colleagues [48],
afterwards could not demonstrate additional risk associ-
ated with increased relative wall thickness in those classi-
fied as hypertrophic. These data may suggest a smaller
independent risk associated with increased wall thickness
in hypertensive patients without LVH criteria.
Even though the additional prognostic role of geometric
patterns over LVH may be lesser than initially supposed,
this classification permits identification of determined
adaptive processes. Concentric remodeling may be related
to specific pathophysiological adaptations, particularly
related to glucose and insulin metabolism [49-51] and
studies in contemporary cohorts have also shown an asso-
ciation of concentric forms with diabetes [52,53].
We believe that geometric classification, with adequate
body size indexing and clearly defined standardization,
may be an alternative and informative strategy to evaluate
adaptive responses, providing information beyond that
provided by classification with respect to left ventricular
hypertrophy.
Role of additional factors in left ventricular mass 
and hypertrophy determination
Gender and body size are clearly identified as predictors of
LV mass and LVH Definitions are usually corrected and/or
stratified for these factors, as seen above. Many others
constitutional factors and exposures may lead to changes
in LV mass. Some of these factors are pathophysiologically
involved in LVH and, moreover, interact among them-
selves, limiting the interpretation of the independent role
of each one.
Gender
Differences in LV mass due to gender, independent of
questions related to body size, may have pathophysiolog-
ical implications. Women have been shown to have an
increased parietal hypertrophic responses to pressure
overload [54,55]., even after body size correction. This
adaptive pattern was demonstrated also in animal models
[56]. The unfavorable prognostic implications of this
hypertrophic response are suggested by the findings of
Liao and coworkers of a 5-fold greater risk of death asso-
ciated with LV hypertrophy indexed by BSA in woman
compared to the risk associated to LVH in men. However,
despite using gender specific cut-offs for LVH, additional
adjustment for obesity was not performed. Employment
of height2.7 indexing allowed to use a unique cut-point of
51 g/m2.7 for both genders [26], reducing the impact of
gender in LVH inference, at least in African-Americans
[57].
Obesity
Although the best strategy to adjust LVM for obesity is a
matter of debate, obesity is increasingly recognized as an
independent predictor of cardiovascular morbidity and
mortality [58,59]. The increase in LV mass related to obes-
ity is probably more than a mere physiologic adaptation.
Obesity has been shown to be independently associated
to LVH [60], particularly in populations with a high prev-
alence of hypertension and other metabolic risk factors
[61,62]. Despite this association, the impact of obesity on
LVH may be less than expected [63], as Iacobellis and col-
leagues [64] have demonstrated that "uncomplicated
obesity" was not a risk factor for LVH when indexed by
either body surface area or height 2.7. As obesity, however,
causes complications, it is frequently accompanied by
additional risk factors. Adjusting by height 2.7 minimizes
the interference of obesity in LV mass estimates (See
above: Body-size Indexing).
Age
LV mass progressively increases during aging [65], partic-
ularly parietal thickness [4], which was seen in both nor-
motensive and hypertensive patients [66]. Heart size
increases during infancy and adolescence due to body size
enlargement and, at this stage, the gender differences
become prominent [67]. The rate of LV mass increase due
to age changes in magnitude [29], weakening its inde-
pendent role at older individuals, when other risk factors
play a greater role [63]. Dannenbeg and coworkers [68]
demonstrated that LV mass did not increase with age in a
healthy sub-sample of The Framingham study, suggesting
that most of the supposed physiological increase is caused
by other determinants. These results are reinforced by
studies in younger subjects where the age-associated
increase in LV mass is partially explained by body size and
blood pressure changes [67]. Nevertheless, it appears pru-
dent to adjust for age in epidemiological investigations
related to LV mass and hypertrophy.Cardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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Ethnicity
LVH is particularly prevalent in African-Americans
[5,62,69-72]. In these analyses, two particular aspects
deserve consideration. An increased crude prevalence of
LVH in African-Americans and Hispanics is more evident
using height-indexed LV mass than with body surface
area-indexed LV mass [71], suggesting that obesity may
partially explain the reported ethnic differences. Further-
more, adaptive response to hypertension may differ across
ethnic groups. Hypertensive African-Americans, in com-
parison with hypertensive whites, have increased relative
wall thickness, resulting in an increased frequency of con-
centric remodeling, given equivalent LV mass estimates
[72,73]. However, Afro-American ancestry has been iden-
tified as an independent risk factor for LVH [74].
Clinical correlates of left ventricular 
hypertrophy
Several factors have been shown repeatedly in epidemio-
logic studies to associate with LVH. Investigation and
prognostication based on LVH should take these factors in
the account.
Blood Pressure and Hypertension
Numerous population based studies have unequivocally
shown an association between hypertension and LVH
[4,5,65,75]. Other reports usually stratify their analysis by
or restrict to those with hypertension to allow better eval-
uation of additional risk factors [45,73,76,77]. It is inter-
esting that even within the normal range, increases in
blood pressure is related to an increased LV mass [67].
This increment may be attributed to the classical patho-
physiological concept of hypertrophic response to
increased overload, although neuro-humoral and genetic
factors have been also implicated [78]. LVH association
with hypertension is so evident that it is recognized as tar-
get organ damage in hypertensive disease by several clini-
cal practice guidelines, representing an intermediate
unfavorable prognostic marker [79,80].
Diabetes and The Metabolic Syndrome
Together with obesity and hypertension, diabetes has
been implicated as an important determinant of left ven-
tricular mass in most population-based studies
[5,52,62,81,82]. Myocardial and systemic mechanisms, as
an increased extra-cellular matrix, vascular hypertrophy
and vasoconstriction [83], have been attributed to this
hypertrophic response.
An adaptive response has been shown to diverse degrees
of altered carbohydrate metabolism, as in Cardiovascular
Health Study [82] and in The Strong Heart Study cohort,
where diabetes [52], impaired glucose tolerance [84] and
insulin levels[85] where associated with increased LV
mass. Although associated with an increase in left ven-
tricular mass, hyperinsulinemia [49] and insulin resist-
ance [50] show a stronger association with concentric
remodeling. Concentric hypertrophy is more pronounced
in diabetes presenting with microalbuminuria [51,86].,
which could imply a progressive adaptive process.
A gender difference in the left ventricular response to dia-
betes, with an increase in parietal thickening, rather than
hypertrophy, being prominent in women has been sug-
gested [81,85,87].
LV mass increase is also seen in individuals with other
known risk factors, as in those linked to the metabolic
syndrome [62,88]., where pathophysiological aspects
related to this syndrome may directly affect ventricular
adaptive mechanisms.
Other Risk Factors
A multitude of other factors have been shown to be inde-
pendently related to LV mass. It should be emphasized
that estimates of the relative magnitude of these factors
varies according to the degree of adjustment for other
known risk factors in statistical modeling. Primary valvu-
lar and myocardial disease are clearly related to LV mass
increase but will not be subject of our review.
Environmental exposures such as alcohol consumption
[89], salt intake [90], smoking [4,89]. and increased lei-
sure-time physical activity in men [91] have been associ-
ated to increased LV mass. Other factors such as blood
lipids, pulmonary function, the heart rate and hematocrit
have also been implicated but with some inconsistency
among different studies [4,75,92,93]. Also, low weight at
1 year-old has been suggested as LV hypertrophy risk fac-
tor, concordant with Barker's Theory of the fetal and early
life origin of chronic disease[94].
Clinical validity and impact of such factors is controver-
sial, but it may be important to consider them as relevant
potential confounders in epidemiological studies investi-
gating the role of novel risk factors in LVH and the role of
LVH in disease prediction.
Reproducibility
Each step in LV mass measurement is a potential source of
variability. In M-mode measurement, differences of
approximately 5% may translate into differences in LV
mass between 8% and 15% [95], which can represent
about 50 g. This variability can be attributed particularly
to the measurement of wall thicknesses and border layer
definition [96-98]. Reproducibility is slightly better using
the ASE rather than the Penn convention [98]. Additional
smaller differences in left ventricular volume determina-
tions can also be attributed to changes in body position or
circulatory loading conditions [99].Cardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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Intraobserver M-mode measurements may vary about 5%
between echocardiographic studies, while interobserver
variability may reach 15%. Some trials retesting patients
found differences of up to 30 g between tests [100,101].
When all sources of variability are taken into account, dif-
ferences in the estimates are not small, since they
approach a difference in LV mass values that is associated
with a clinically important increased cardiovascular risk.
Strategies such as core laboratory reading, strict protocols
and regular training may keep this variability in an accept-
able range for clinical and epidemiologic studies.
Comparison with other Imaging Methods
Autopsy is classically employed as the gold standard in
heart hypertrophy studies, because it objectively measures
LV mass. However, use of reported data is complicated by
the fact that macroscopic LVH definition criteria are usu-
ally more varied than those used in non-invasive testing
[102-105], as well as by the fact that different studies have
applied different indexing techniques for body size.
From a histological point of view, myocytes hyperplasia is
uncommon in adults. Pathologic studies and animal
models suggest evaluating hypertrophy suggest that myo-
cytes keep their integrity and functionality until an
increase up to 50 -70% above normal [106]. This is con-
cordant with the Linzbach's critical level of LVH, above
which cytopathological changes occur with disruption of
myocardial tissue integrity and functioning [107].
LV mass can also be calculated from angiography.
Although diverse formulas have been employed and vali-
dated [13], correlation with echocardiographic calculated
LV mass is fair to moderate, with correlation coefficients
of between 0.50 and 0.70 [108].
Radioisotopic gated myocardial perfusion imaging with
99mTc-Sestamibi has been employed to estimate LV mass.
Its accuracy is limited by image construction and process-
ing variability, resulting in a limited correlation with
echocardiographic LV mass [109]. However, Maruyama
and coworkers [110] found a good correlation coefficient
(r = 0.96) between gated 99mTc-tetrofosmin myocardial
perfusion and echocardiographic based LV mass estima-
tions, using an automated quantitative software.
Newer imaging methods have been employed in LV mass
determination. Computed tomography has a good corre-
lation with necropsy findings (r = 0.97). In vivo intrar-
eader variability was estimated to be equivalent to 19 g
and intereader 28 g [111]. Magnetic resonance imaging
(MRI) has emerged as a highly reproducible and accurate
imaging methodology in the evaluation of LV geometry
and mass [112-115]. As a result, it is of great value in eval-
uating distorted ventricles and its high accuracy may par-
tially counterbalance its costs, due to the smaller samples
needed. However, echocardiography costs are considera-
bly lower in most of the countries, there is no significant
radiation exposure [116], and just a few-population based
studies have used these costly and less available newer
imaging techniques.
Real time three-dimensional echocardiography is still
experimental, but has incorporated technical advantages
in image acquisition and processing. This method may
permit accurate real time LV mass measurement without
the caveats of geometrical assumptions. Preliminary data
suggest that real time three-dimensional echocardiogra-
phy is at least as accurate and reproducible as MRI calcu-
lations [117]. Contrast echo with microbubbles also
permits increasing accuracy, particularly in those with
inadequate acoustic windows or with distorted ventricles
[118].
Conclusion
LV mass estimation and LVH diagnosis role in cardiovas-
cular disease management is based on epidemiological
research and also on clinical grounds. Despite more than
30 years of use echocardiography-based LVH calculation
and definition are still variable among ultrasound techni-
cians and laboratories around the world, leading to incon-
sistency among epidemiological studies and possibly
limiting its clinical application. Several technical aspects
of the echocardiographic exam can generate substantial
errors in LV estimations, some of them equivalent in size
to those expected to result from pathophysiological proc-
esses and therapeutic strategies. Also, adequate indexing
for body size seems to be a critical point in defining path-
ological hypertrophy. LV mass is closely related to the
other known cardiovascular risk factors, that must be
taken into account concomitantly. Finally, since the risk
associated to LV mass appears to be progressive, without a
clear threshold, additional input can be added at different
baseline risks, defined by the prevalence of other known
cardiovascular risk factors. The addition of multiple newer
markers, however, leads to a small increment in risk strat-
ification capacity over formulas applying only classical
risk factors [119]. Despite these limitations, the role of
echocardiography in LV mass determination is of great
clinical value.
Considering all the aspects reviewed, use of echocardiog-
raphy in clinical studies must be standardized applying
already defined criteria. In delineating a study, if two-
dimensional is impractical, then two-dimensional guided
M-mode, using ASE criteria and Devereux modified for-
mula, will allow estimation of LV mass with an acceptable
level of accuracy. Additionally, adequate adjustment of
related covariates must be undertaken. LHV/Ht2.7greater
than 51g/m2.7 appears to be a reliable criteria to defineCardiovascular Ultrasound 2005, 3:17 http://www.cardiovascularultrasound.com/content/3/1/17
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LVH, and the inclusion of a measurement of relative wall
thickness, individually or classified as geometric patterns
improves the identification of the adaptive mechanisms
involved.
Echocardiography is widely available all over the world
and major technical improvements have been achieved in
the last two decades. Given careful attention with respect
to the technical aspects appraised in this review, echocar-
diography will remain a safe, inexpensive and accurate
tool for both the clinical diagnosis and epidemiologic
investigation of left ventricular hypertrophy
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